• » Corporate
• Letter from the CEO
• Company Fact Sheet
• Quality Policy and Objectives
• » Leadership
• Peter Lea, Ph.D.
• Claude Ricks
• Andrew Morris, M.Sc., MBA
• Thomas E.T. O'Connor
• Kate Smith
• Sasi Mudumba, Ph.D.
• Denis Bosc, Ph.D.
• Darryl Burke
• Geihan Rizkalla, M.Sc., CQM
• » Board of Directors
• » Investors
• » News & Media
• Press Releases 2010
• Press Releases 2009
• Press Releases 2008
• » Career Openings
• » Contact Us

Press Releases

SQI Diagnostics to Present at AACC 40th Annual Oak Ridge Conference - Breakthrough Technologies for Clinical Diagnostics

Released: Apr 14, 2008

a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that it will be presenting at the AACC 40th Annual Oak Ridge Conference - Breakthrough Technologies for Clinical Diagnostics on April 17 at 11:30 am (PST) at The Fairmont, San José, CA. The presentation will focus on the sensitivity and specificity of anti-citrullinated peptide (CCP) detection, a key component of SQI Diagnostics’ multi-analyte QuantiSpot™ RA panel on SQI Diagnostics’ automated SQiDworks™ platform. The QuantiSpot™ RA panel is to be used to aid in the diagnosis of rheumatoid arthritis.

"The invitation to speak at such a prestigious conference demonstrates the growing interest in our breakthrough technologies and reflects the progress we have made at SQI," said Claude Ricks, President and CEO of SQI Diagnostics. "Positive results of our recently completed internal study using the SQiDworks™ automated platform to analyze our QuantiSpot™ RA panel, which tests for biomarkers used in the diagnosis of rheumatoid arthritis, specifically our novel method for anti-CCP detection, generated significant interest. The results further support our belief that our automated SQiDworks™ and multiplexed QuantiSpot™ system has the technical performance and functional ability to meet the growing demands of laboratories for diagnostic innovations that can save time and money."

The Company will also present at the conference a poster entitled "Specificity and sensitivity of a novel anti-citrullinated peptide antibody assay in a four-analyte multiplexed QuantiSpot™ rheumatoid arthritis test system."

About SQI Diagnostics
SQI Diagnostics is a medical systems automation company focused on evolving laboratory-based biomarker testing. Using automation and proprietary miniaturization technologies, SQI Diagnostics significantly improves the economies of scale for laboratories performing multi-analyte biomarker testing, allowing them to deliver patient results faster, using less labor, and fewer resources. SQI Diagnostics' initial products target the autoimmune disease market, with initial products for rheumatoid arthritis and antiphospholipid syndrome scheduled for launch in 2008. SQI Diagnostics is based in Toronto, Canada. For further information please visit www.sqidiagnostics.com.

For further information please contact:

Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.

This release was prepared by management of the Company who takes full responsibility for its contents. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.